GNPX Genprex, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GNPX matters now
Genprex, Inc. (GNPX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.56 with +0.79% on the session and $913.7K in market capitalization; recent performance reads 1-month -24.87% and YTD -66.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.5M, and EPS of $-0.64. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1479.0%.
The latest indexable market news headline is "Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes LONGNECKER BRENT M filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.24
P/S
0.00
EV/EBITDA
1.07
DCF Value
$7.64
FCF Yield
-1479.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-247.3%
ROA
-82.4%
ROIC
-94.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.5M | $-0.64 |
| Q4 2025 | $0.00 | $-3.8M | $-1.15 |
| FY 2025 | $0.00 | $-16.2M | $-17.40 |
| Q3 2025 | $0.00 | $-3.8M | $-5.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.96
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.